Literature DB >> 16703880

Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status.

Joshua Seinfeld1, Bette K Kleinschmidt-Demasters, Shalini Tayal, Kevin O Lillehei.   

Abstract

OBJECT: Desmoid-type fibromatoses are a locally invasive soft-tissue lesion that is most commonly encountered in abdominal sites. The tumor also affects head and neck areas, particularly the supraclavicular region, where it may encase and distort the brachial plexus and compromise neurovascular structures. Neurosurgeons may be called on to treat desmoid-type fibromatoses in these sites. The authors describe their experience in treating four patients with desmoid-type fibromatoses involving the brachial plexus and report the results of immunohistochemical analysis of the tumors.
METHODS: Gross-total excision with nerve sparing was the first-line therapy of choice, although the surgery was challenging. Intraoperative identification of the site of tumor origin from musculoaponeurotic tissues by the neurosurgeon was necessary in two of the four cases to achieve a correct frozen section or final pathological diagnosis. Immunostaining for c-KIT (CD117) was undertaken in all cases in light of a previous report of positive CD117 immunoreactivity in abdominal desmoid-type fibromatoses. All four tumors manifested weak focal immunostaining for c-KIT. One of the patients was given adjuvant imatinib mesylate therapy, with limited success. Subsequent polymerase chain reaction testing revealed that three of the four tumors manifested a single base pair change in exon 10 of the c-KIT gene (A to C in two cases and A to G in one case). There was local recurrence in three patients, despite gross-total excision. With the combination of surgery and radiation therapy, local disease control was achieved in three of the four patients.
CONCLUSIONS: This represents the first report of c-KIT sequencing in desmoid-type fibromatoses and suggests a possible biological basis for continuing to explore the use of adjuvant imatinib mesylate therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16703880     DOI: 10.3171/jns.2006.104.5.749

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.

Authors:  Jean-Emmanuel Kurtz; Irène Asmane; Anne-Claire Voegeli; Agnès Neuville; Armelle Dufresne; Valère Litique; Christine Chevreau; Jean-Pierre Bergerat
Journal:  Sarcoma       Date:  2010-03-17

2.  Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.

Authors:  A Dufresne; F Bertucci; N Penel; A Le Cesne; B Bui; M Tubiana-Hulin; I Ray-Coquard; D Cupissol; C Chevreau; D Perol; A Goncalves; M Jimenez; P P Bringuier; J Y Blay
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

3.  Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.

Authors:  Maxim Ivanov; Konstantin Laktionov; Valery Breder; Polina Chernenko; Ekaterina Novikova; Ekaterina Telysheva; Sergey Musienko; Ancha Baranova; Vladislav Mileyko
Journal:  J Transl Med       Date:  2017-01-31       Impact factor: 5.531

4.  Desmoid tumour of the brachial plexus.

Authors:  Orege Juliette; Koech Florentius; Ndiangui Francis; Benson Ndegwa Macharia; Mbaruku Neema
Journal:  Case Rep Surg       Date:  2013-06-12

5.  Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.

Authors:  Armelle Dufresne; Laurent Alberti; Mehdi Brahmi; Sarah Kabani; Héloïse Philippon; David Pérol; Jean Yves Blay
Journal:  BMC Cancer       Date:  2014-08-29       Impact factor: 4.430

6.  Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.

Authors:  Katsuhiro Masago; Shiro Fujita; Miho Muraki; Akito Hata; Chiyuki Okuda; Kyoko Otsuka; Reiko Kaji; Jumpei Takeshita; Ryoji Kato; Nobuyuki Katakami; Yukio Hirata
Journal:  BMC Cancer       Date:  2015-11-16       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.